David Ricks
Eli Lilly’s chairman and CEO since 2017, who rode the GLP-1 obesity-and-diabetes boom to make Lilly one of the most valuable companies in the world.
Pay vs performance
what happened while he earned itNo score, no opinion. Compensation is filed; stock and S&P are market returns over the window shown; revenue and EPS are latest reported vs the prior year. You decide.
Why this pay?
- His fiscal 2025 pay was $36.7 million — reportedly the highest among Big Pharma CEOs that year. A large part of the year-over-year increase was the change-in-pension-value line, which more than doubled. A separately circulated "$114 million" figure is realized/vested equity value, not the SCT total.
Quick facts
Compensation breakdown
DEF 14AThe pension line more than doubled to $4.45M, driving much of the increase. The "$114M" figure quoted elsewhere is realized value, not the SCT. Source: Eli Lilly 2026 Proxy (FY2025) →
Compensation history
salary + cash vs stock, from the proxiesRelated intelligence
every filing on Eli Lilly, one hop awayCareer
Compare pay with
Every figure ties to a filing. Compensation is the total from Eli Lilly's Summary Compensation Table for FY2025(grant-date values, which can differ from what an executive realizes when awards vest). We publish what the filings say, and we don't grade people. Photo: Virginia Office of the Governor / CC BY 4.0 / Wikimedia Commons.